Clinical Evaluation of an Immunochromatographic-Based IgM/IgG Antibody Assay (GenBody™ COVI040) for Detection of Antibody Seroconversion in Patients with SARS-CoV-2 InfectionArticle Published on 2021-03-172022-10-31 Journal: Diagnostics [Category] COVID-19, [키워드] 95% confidence interval Accuracy acute respiratory syndrome anti-SARS-CoV-2 IgM antibody approval clinical collected coronavirus coronavirus disease COVID-19 COVID-19 patients detection diagnostic diagnostic accuracy study diagnostic test drug evaluate food IgG IgM IgM/IgG immunochromatography Immunoglobulin Immunoglobulin G immunoglobulin M in vitro Korean MONITOR negative control sample Patient polymerase chain PSO Safety SARS-CoV-2 SARS-CoV-2 antibody sensitivity Sensitivity and specificity Seroconversion South specificity symptom onset tested were used [DOI] 10.3390/diagnostics11030537 PMC 바로가기 [Article Type] Article
The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort studyResearch Paper Published on 2021-03-152022-10-28 Journal: Aging (Albany NY) [Category] COVID-19, MERS, [키워드] 28-day mortality 95% CI acute respiratory distress adverse events ascorbic acid Coronavirus disease 2019 Critical determine Efficacy and safety Efficiency event High-dose vitamin C IMPROVE inflammatory reaction intravenous Loading dose Mortality multiple organ failure oxygen support Patient reduce reduced retrospective cohort study risk Safety Sepsis Standard therapy suggested Support syndrome therapy Vitamin C was reduced [DOI] 10.18632/aging.202557 PMC 바로가기 [Article Type] Research Paper
Occupational Health and Safety Measures in German Outpatient Care Services during the COVID-19 Pandemic: A Qualitative StudyArticle Published on 2021-03-142022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] analysed Analysis Care coronavirus disease COVID-19 described effective Health health threats hygiene identify information initial interview measure needs occupational occupational health and safety Outpatient Outpatient Care pandemic participated Personal protective equipment PPE PROTECT Qualitative Quantitative Regulation Safety service social distancing threat transcribed were recorded [DOI] 10.3390/ijerph18062987 PMC 바로가기 [Article Type] Article
Women Face to Fear and Safety Devices During the COVID-19 Pandemic in Italy: Impact of Physical Distancing on Individual Responsibility, Intimate, and Social RelationshipPublic Health Published on 2021-03-122022-10-31 Journal: Frontiers in Public Health [Category] Coronavirus, MERS, SARS, [키워드] collected Community Contagion COVID-19 COVID-19 pandemic Device Epidemic face fear form Government greater Health health citizenship highlight Impact individual Intervention involved Isolation Italy lockdown maintain majority management manifestation methodology pandemic Perspective physical distancing produced public health questionnaire recommendation reconstructed relationship Research responsibility Safe Safety Social responsibility state women [DOI] 10.3389/fpubh.2021.622155 PMC 바로가기 [Article Type] Public Health
Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trialClinical Trial Published on 2021-03-122023-06-24 Journal: Vaccine [Category] 신종인플루엔자, [키워드] High-dose IIV4-HD immunogenicity influenza vaccination pediatric Safety [DOI] 10.1016/j.vaccine.2021.02.014 [Article Type] Clinical Trial
Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain, January and February 2021Rapid Communication Published on 2021-03-112022-10-31 Journal: Eurosurveillance [Category] COVID-19, [키워드] administration adverse events Adverse reaction Collaborating COVID-19 injection intramuscular ipsilateral Lymph node monitoring mRNA vaccination mRNA vaccine mRNA-based COVID-19 vaccine Safety Spain supraclavicular lymphadenopathy Vaccine vaccine injection WHO [DOI] 10.2807/1560-7917.ES.2021.26.10.2100193 PMC 바로가기 [Article Type] Rapid Communication
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trialCOVID-19(FLARE) 외래 환자의 조기 항바이러스 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-03-082022-09-01 Journal: Trials [Category] SARS, 임상, 진단, 치료기술, 치료제, [키워드] 24 hours 48 hour 48 hours absence admitted to ICU aetiology age ALT Analysis Anosmia anticipated antiviral therapy Antiviral treatment antivirals Appendix Arm arrhythmia AST Asthma Asymptomatic Autoimmune blinded to treatment Blinding blood sample BMI Breastfeeding childbearing potential Cholangitis chronic chronic hepatitis Chronic kidney disease chronic liver disease chronic respiratory disease cirrhosis clinical condition collected combination therapy Comorbidity concealed Concomitant concomitant medications conducted COPD coryza cough COVID-19 COVID-19 disease COVID-19 vaccine criteria current Date Day decrease defined Deleterious detectable diabetes died disease dissemination dose double-blind Duration early treatment effective EGFR element enrolled enrolment Ethnicity examined exclusion criteria factorial design Favipiravir female female participant Fever followed by Free Gender headache heart disease Hepatitis hepatotoxicity HIV infection hospital hospitalisation hypersensitivity hypertension in viral include inclusion criteria ingredient investigator investigators Ischaemic heart disease Kidney disease liver Liver disease London Lopinavir Lopinavir/ritonavir malaise male participant male participants measure medication Mutation myalgia Myocardial infarction no symptom non-hospitalised not limited number obesity objective observational studies observational study oral outcome Outpatient outpatients participant Participants partner percentage pharmacokinetic phase IIa Placebo placebo-controlled placebo-controlled trial positive presence or absence Primary outcome Proportion of participant Protease inhibitor protocol randomised randomised controlled trial Rate Registered Registration respiratory Respiratory disease risk Ritonavir Safety Saliva saliva samples Sample size SARS-CoV-2 secondary Secondary outcomes Shortness of breath smoker smoking smoking status Stage status steatohepatitis Stool Study protocol supplementary material Symptom symptom onset symptomatic tested therapy Toxicity Treatment treatment allocation Trial trial medication Trial registration undetectable United Kingdom upper respiratory tract vaccine trial valvular valvular heart disease Viral Viral load website with COVID-19 [DOI] 10.1186/s13063-021-05139-2 PMC 바로가기 [Article Type] Letter
Importance of brucellosis control programs of livestock on the improvement of one healthReview Published on 2021-03-082023-05-31 Journal: The Veterinary Quarterly [Category] Fulltext, 조류인플루엔자, [키워드] bovine brucellosis cattle control programs livestock production milk Safety [DOI] 10.1080/01652176.2021.1894501 PMC 바로가기 [Article Type] Review
Percutaneous Dilational Tracheostomy in a Patient With SARS-CoV-2 (COVID-19) Disease: A Case Report With Implications in Staff SafetyAnesthesiology Published on 2021-03-082022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome air-contamination Contamination coronavirus COVID-19 healthcare high-risk procedure Infection mechanical ventilation support negative-pressure room operative Patient patient with COVID-19 Percutaneous percutaneous dilational tracheostomy performed Personal protective equipment Pneumonia reduce report risk Safety SARS-CoV-2 SARS-CoV-2 (COVID-19) staff surgeon surgical personnel tracheostomy [DOI] 10.7759/cureus.13769 PMC 바로가기 [Article Type] Anesthesiology
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials단회 투여 및 ChAdOx1 nCoV-19(AZD1222) 백신의 면역원성 및 효능에 대한 추가 투여 시간의 영향: 4건의 무작위 시험에 대한 통합 분석Meta-Analysis Published on 2021-03-062022-09-10 Journal: Lancet (London, England) [Category] MERS, SARS, 임상, [키워드] 1:1 95% CI addition administration Ageusia All participants Analysis Anosmia antibody antibody levels Antibody Response Antibody responses approved assigned AstraZeneca AZD1222 baseline binding antibody booster dose booster doses Brazil category ChAdOx1 ChAdOx1 nCoV-19 Clinical research Coalition control group control vaccine cough COV005 COVID-19 COVID-19 disease COVID-19-related death Cutoff death defined described dose doses double-blind Efficacy Emergency use Endpoint Evidence evidence of exclusion exploratory Exploratory analyses Exploratory analysis Fever finding first dose FIVE Follow-up for inclusion foundation funding geometric mean geometric mean ratio GMR had no Hospital admission immunoassay immunogenicity immunogenicity data independent indicated individual Infection initial Innovation interim analysis ISRCTN89951424 less lower dose Medicine Medicines Medicines and Healthcare products Regulatory Agency Melinda Gate Melinda Gates N protein NAAT NAAT-positive swab network neutralisation NIHR no evidence of nucleic acid nucleic acid amplification nucleic acid amplification test observation offered Older outcomes Oxford pandemic participant phase 2/3 phase 3 study positive swab primary analysis primary endpoint Primary outcome prime-boost interval priming PROTECT pseudovirus randomised controlled Randomised trial Randomly receive receiving recruited regimen Registered regulatory authority response Safety saline placebo SARS-COV-2 infection SARS-CoV-2 N protein second dose secondary Serious Adverse Events seronegative Seven Shortness of breath single-blind Single-dose South South Africa Standard dose subset supported Swab swabs Symptom symptomatic COVID-19 disease symptomatic infection Telle the primary endpoint the timing the vaccine Trial vaccination Vaccine vaccine efficacy Valley Viral Viral particles [DOI] 10.1016/S0140-6736(21)00432-3 PMC 바로가기 [Article Type] Meta-Analysis